<DOC>
	<DOCNO>NCT00886821</DOCNO>
	<brief_summary>The purpose study determine safety tolerability CVX-096 adult , type 2 diabetic patient .</brief_summary>
	<brief_title>A Safety Pharmacokinetic Study CVX-096 Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male and/or female patient ( female woman nonchildbearing potential ) historical diagnosis type 2 diabetes mellitus , currently treat metformin dose near maximum . Hb A1c 710 % . Fasting Cpeptide &gt; 0.4 nmol/L . History clinically significant chronic condition T2DM well control either diet medication . Patients pancreatitis consider high risk pancreatitis . History contraindication metformin therapy . Previous treatment approve investigational GLP 1 mimetic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Phase 1 Type 2 diabetes CVX-096 diabetes mellitus</keyword>
	<keyword>adult-onset diabetes mellitus</keyword>
	<keyword>non-insulin dependent</keyword>
</DOC>